Prediction of Reproductive Outcomes According to Different Serum Anti-Müllerian Hormone Levels in Females Undergoing Intracystoplasmic Sperm Injection

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Brugo Olmedo, Santiago ^a   De Vincentiis, Sabrina ^a   De Martino, Evelyn ^a   Bedecarrás, Patricia ^b   Blanco, Ana María ^c   Freire, Analía ^b   Buffone, Mariano G ^a,d   Rey, Rodolfo A ^b  

^a Centro Médico Seremas   (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c Centro de Estudios Bioquímicos Andrológicos y Ginecológicos   (Argentina)

^d INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; MUELLERIAN INHIBITING FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; FEMALE; FEMALE INFERTILITY; HORMONE BLOOD LEVEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREGNANCY RATE; REPRODUCTION; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; ANTI-MULLERIAN HORMONE; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; MENSTRUAL CYCLE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PROGNOSIS; REPRODUCTION; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84884214073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075685     Document Type: Article

References (44)

1. te Velde ER, Pearson PL, (2002) The variability of female reproductive ageing. Hum Reprod Update 8: 141-154. doi:10.1093/humupd/8.2.141. PubMed: 12099629.
2. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T, et al. (2011) External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. Reprod Biomed Online 23204-206:: S1472-S6483. 11)00272-0. PII. doi:10.1016/j.rbmo.2011.05.006.
3. Broekmans FJ, Knauff EA, te Velde ER, Macklon NS, Fauser BC, (2007) Female reproductive ageing: current knowledge and future trends. Trends Endocrinol Metab 18: 58-65. S1043- doi:10.1016/j.tem.2007.01.004. PubMed: 17275321. 2760(07)00005-7. PII. doi:10.1016/j.tem.2007.01.004.
4. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ, (2007) Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 87: 764-775. S0015- doi:10.1016/j.fertnstert.2006.11.006. PubMed: 17239869. 0282(06)04377-9. PII. doi:10.1016/j.fertnstert.2006.11.006.
5. Broer SL, Mol BW, Hendriks D, Broekmans FJM, (2009) The role of antiMüllerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 91: 705-714. doi:10.1016/j.fertnstert.2007.12.013. PubMed: 18321493.
6. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB, (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12: 685-718. doi:10.1093/humupd/dml034. PubMed: 16891297.
7. Feyereisen E, Méndez Lozano DH, Taieb J, Hesters L, Frydman R, et al. (2006) Anti-Müllerian Hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online 12: 695-703. doi:10.1016/S1472-6483(10)61081-4. PubMed: 16792844.
8. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, et al. (2010) Anti-Müllerian Hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16: 113-130. doi:10.1093/humupd/dmp036. PubMed: 19793843. dmp036. PII. doi:10.1093/humupd/dmp036.
9. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, et al. (2011) AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 17: 46-54. doi:10.1093/humupd/dmq034. PubMed: 20667894. dmq034. PII. doi:10.1093/humupd/dmq034.
10. Anderson RA, Nelson SM, Wallace WH, (2012) Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 71: 28-33. doi:10.1016/S0378-5122(12)70112-3. PubMed: 22119275.
11. Josso N, Picard JY, Rey R, di Clemente N, (2006) Testicular Anti-Müllerian Hormone: History, Genetics, Regulation and Clinical Applications. Pediatr Endocrinol Rev 3: 347-358. PubMed: 16816803.
12. Vigier B, Picard JY, Tran D, Legeai L, Josso N, (1984) Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology 114: 1315-1320. doi:10.1210/endo-114-4-1315. PubMed: 6546716.
13. Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, et al. (2000) Anti-Müllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 31: 1202-1208. doi:10.1053/hupa.2000.18498. PubMed: 11070112.
14. Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, et al. (1996) Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 174: 958-965. doi:10.1016/S0002-9378(96)70333-2. PubMed: 8633676.
15. Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, et al. (2010) Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 95: 5003-5010. doi:10.1210/jc.2010-0930. PubMed: 20719830. jc.2010-0930. PII. doi:10.1210/jc.2010-0930.
16. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A, (1997) Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 67: 962-965. doi:10.1016/S0015-0282(97)81417-3. PubMed: 9130910.
17. Pigny P, Jonard S, Robert Y, Dewailly D, (2006) Serum Anti-Müllerian Hormone as a Surrogate for Antral Follicle Count for Definition of the Polycystic Ovary Syndrome. J Clin Endocrinol Metab 91: 941-945. PubMed: 16368745.
18. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, et al. (2000) Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 85: 540-544. doi:10.1210/jc.85.2.540. PubMed: 10690852.
19. Cook CL, Siow Y, Taylor S, Fallat ME, (2000) Serum Müllerian inhibiting substance levels during normal mestrual cycles. Fertil Steril 73: 859-861. doi:10.1016/S0015-0282(99)00639-1. PubMed: 10731554.
20. La Marca A, Stabile G, Artenisio AC, Volpe A, (2006) Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum Reprod 21: 3103-3107. doi:10.1093/humrep/del291. PubMed: 16923748.
21. Hehenkamp WJK, Looman CWN, Themmen APN, de Jong FH, te Velde ER, et al. (2006) Anti-Müllerian Hormone Levels in the Spontaneous Menstrual Cycle Do Not Show Substantial Fluctuation. J Clin Endocrinol Metab 91: 4057-4063. doi:10.1210/jc.2006-0331. PubMed: 16804046.
22. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R, (1990) An enzyme linked immunoassay for anti-Müllerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 70: 23-27. doi:10.1210/jcem-70-1-23. PubMed: 1688440.
23. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, et al. (1990) An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 70: 16-22. doi:10.1210/jcem-70-1-16. PubMed: 2294129.
24. Baker ML, Metcalfe SA, Hutson JM, (1990) Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab 70: 11-15. doi:10.1210/jcem-70-1-11. PubMed: 2403569.
25. Rey RA, Belville C, Nihoul-Fékété C, Michel-Calemard L, Forest MG, et al. (1999) Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 84: 627-631. doi:10.1210/jc.84.2.627. PubMed: 10022428.
26. Cook CL, Siow Y, Brenner AG, Fallat ME, (2002) Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 77: 141-146. doi:10.1016/S0015-0282(01)02944-2. PubMed: 11779604.
27. Fréour T, Mirallié S, Bach-Ngohou K, Denis M, Barrière P, et al. (2007) Measurement of serum Anti-Müllerian Hormone by Beckman Coulter ELISA and DSL ELISA: Comparison and relevance in Assisted Reproduction Technology (ART). Clin Chim Acta 375: 162-164. doi:10.1016/j.cca.2006.06.013. PubMed: 16860302.
28. Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, et al. (2003) Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18: 328-332. doi:10.1093/humrep/deg043. PubMed: 12571169.
29. Grinspon RP, Ropelato MG, Bedecarrás P, Loreti N, Ballerini MG, et al. (2012) Gonadotrophin secretion pattern in anorchid boys from birth to pubertal age: pathophysiological aspects and diagnostic usefulness. Clin Endocrinol (Oxf) 76: 698-705. doi:10.1111/j.1365-2265.2011.04297.x. PubMed: 22098623.
30. Olmedo SB, Rawe VY, Nodar FN, Galaverna GD, Acosta AA, Chemes HE, (2000) Pregnancies established through intracytoplasmic sperm injection (ICSI) using spermatozoa with dysplasia of fibrous sheath. Asian J Androl 2: 125-130. PubMed: 11232789.
31. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M, (2004) Inhibin B and anti-Müllerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG: An International Journal of Obstetrics and Gynaecology 111: 1248-1253. doi:10.1111/j.1471-0528.2004.00452.x. PubMed: 15521870.
32. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, et al. (2005) Antral follicle count, anti-Müllerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 112: 1384-1390. doi:10.1111/j.1471-0528.2005.00670.x. PubMed: 16167941.
33. Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G, et al. (2005) Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 20: 915-922. PubMed: 15665015.
34. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, et al. (2006) Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21: 2022-2026. doi:10.1093/humrep/del127. PubMed: 16679324.
35. McIlveen M, Skull JD, Ledger WL, (2007) Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 22: 778-785. PubMed: 17114197.
36. Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG, et al. (2007) AntiMüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 87: 223-226. doi:10.1016/j.fertnstert.2006.06.019. PubMed: 17081531.
37. Nelson SM, Yates RW, Fleming R, (2007) Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum Reprod 22: 2414-2421. doi:10.1093/humrep/dem204. PubMed: 17636277. dem204. PII. doi:10.1093/humrep/dem204.
38. Fridén B, Sjöblom P, Menezes J, (2011) Using anti-Müllerian hormone to identify a good prognosis group in women of advanced reproductive age. Aust N Z J Obstet Gynaecol 51: 411-415. doi:10.1111/j.1479-828X.2011.01374.x. PubMed: 21988118.
39. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N, (2010) A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 93: 855-864. doi:10.1016/j.fertnstert.2008.10.042. PubMed: 19046583.
40. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM, (2002) Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77: 468-471. doi:10.1016/S0015-0282(01)03201-0. PubMed: 11872196.
41. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, et al. (2004) Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82: 1323-1329. doi:10.1016/j.fertnstert.2004.03.061. PubMed: 15533354.
42. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, et al. (2006) Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 21: 159-163. doi:10.1093/oxfordjournals.humrep.a002489. PubMed: 16123085.
43. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP, (2007) Anti-Müllerian Hormone as a predictor of IVF outcome. Reprod Biomed Online 14: 602-610. doi:10.1016/S1472-6483(10)61053-X. PubMed: 17509203.
44. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, et al. (2008) Anti-Müllerian Hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 16: 664-670. doi:10.1016/S1472-6483(10)60480-4. PubMed: 18492370.